Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Interferon-γ release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis
European Respiratory Journal, Volume 37, No. 1, Year 2011
Notification
URL copied to clipboard!
Description
Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent infection with Mycobacterium tuberculosis in many countries. However, the role of IGRAs for the diagnosis of active tuberculosis (TB) remains unclear. Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) and quality assessment of diagnostic accuracy studies (QUADAS) guidelines, we searched PubMed, EMBASE and Cochrane databases to identify studies published in January 2001-November 2009 that evaluated the evidence of using QuantiFERON-TB® Gold in-tube (QFT-G-IT) and T-SPOT.TB® directly on blood or extrasanguinous specimens for the diagnosis of active TB. The literature search yielded 844 studies and 27 met the inclusion criteria. In blood and extrasanguinous fluids, the pooled sensitivity for the diagnosis of active TB was 80% (95% CI 75-84%) and 48% (95% CI 39-58%) for QFT-G-IT, and 81% (95% CI 78-84%) and 88% (confirmed and unconfirmed cases) (95% CI 82-92%) for T-SPOT.TB®, respectively. In blood and extrasanguinous fluids, the pooled specificity was 79% (95% CI 75-82%) and 82% (95% CI 70-91%) for QFT-G-IT, and 59% (95% CI 56-62%) and 82% (95% CI 78-86%) for T-SPOT.TB®, respectively. Although the diagnostic sensitivities of both IGRAs were higher than that of tuberculin skin tests, it was still not high enough to use as a rule out test for TB. Positive evidence for the use of IGRAs in compartments other than blood will require more independent and carefully designed prospective studies. Copyright©ERS 2011.
Authors & Co-Authors
Sester, Martina
Germany, Homburg
Universitätsklinikum Des Saarlandes Medizinische Fakultät Der Universität Des Saarlandes
Sotgiu, Giovanni
Italy, Sassari
Università Degli Studi Di Sassari
Lange, Christoph G.
Germany, Borstel
Forschungszentrum Borstel - Zentrum Für Medizin Und Biowissenschaften
Giehl, C.
Germany, Saarbrucken
European Research and Project Office Gmbh
Girardi, Enrico
Italy, Rome
Irccs Istituto Nazionale Malattie Infettive Lazzaro Spallanzani
Migliori, Giovanni Battista
Italy, Pavia
Istituti Clinici Scientifici Maugeri Spa – sb
Bossink, Ailko W.J.
Netherlands, Utrecht
Diakonessenhuis Utrecht
Dheda, Keertan U.J.
South Africa, Cape Town
University of Cape Town Lung Institute
Diel, Roland
Germany, Hannover
Hannover Medical School
Domínguez, José A.Blanco
Spain, Madrid
Instituto de Salud Carlos Iii
Lipman, Marc CI
United Kingdom, London
The Royal Free Hospital
Nemeth, Johannes
Switzerland, Basel
Universitätsspital Basel
Ravn, Pernille
Denmark, Hellerup
Gentofte Hospital
Winkler, Stefan
Austria, Vienna
Medizinische Universität Wien
Huitric, Emma
Sweden, Solna
European Centre for Disease Prevention and Control
Sandgren, Andreas
Sweden, Solna
European Centre for Disease Prevention and Control
Manissero, Davide
Sweden, Solna
European Centre for Disease Prevention and Control
Statistics
Citations: 409
Authors: 17
Affiliations: 15
Identifiers
Doi:
10.1183/09031936.00114810
ISSN:
09031936
e-ISSN:
13993003
Research Areas
Infectious Diseases
Study Design
Cohort Study
Study Approach
Systematic review